View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
The FDA has approved gadofosveset trisodium (Vasovist Injection) to enhance images of blood flow in patients undergoing magnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease in adults with known or suspected peripheral vascular disease. An MRA can be conducted without any contrast agent, but radiologists can't interpret the images in 10% to 30% of instances. To evaluate these hard-to-see vessels, radiologists typically use angiography requiring arterial catheterization and contrast media administration. Complications include vessel wall injury and nephrotoxicity.
Vasovist is injected into a peripheral vein, considerably lowering these risks, as well as decreasing patient discomfort and recovery time. Unlike angiography, MRA doesn't expose patients to ionizing radiation.
Potential adverse reactions to Vasovist include allergic reactions and nephrogenic systemic fibrosis, a serious but rare syndrome. A boxed warning and information about this syndrome is included with all drugs containing gadolinium. For more information, visit the FDA's Web site at http://www.fda.gov.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top